What is Genelux Corporation Common Stock?
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 103.36M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 658,828 shares $156k | 0 |
| 3-6months | 626,521 shares $78k | 0 |
| 6-9months | 89,912 shares $26k | 0 |
| 9-12months | 0 | 0 |